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Abstract
Noninvasive biomarkers of anti-tumoral efficacy are of great importance to the development of therapeutic agents. Tumor
oxygenation has been shown to be an important indicator of therapeutic response. We report the use of intracellular
labeling of tumor cells with perfluorocarbon (PFC) molecules, combined with quantitative 19F spin-lattice relaxation rate (R1)
measurements, to assay tumor cell oxygen dynamics in situ. In a murine central nervous system (CNS) GL261 glioma model,
we visualized the impact of Pmel-1 cytotoxic T cell immunotherapy, delivered intravenously, on intracellular tumor oxygen
levels. GL261 glioma cells were labeled ex vivo with PFC and inoculated into the mouse striatum. The R1 of
19F labeled cells
was measured using localized single-voxel magnetic resonance spectroscopy, and the absolute intracellular partial pressure
of oxygen (pO2) was ascertained. Three days after tumor implantation, mice were treated with 2610
7 cytotoxic T cells
intravenously. At day five, a transient spike in pO2 was observed indicating an influx of T cells into the CNS and putative
tumor cell apoptosis. Immunohistochemistry and quantitative flow cytometry analysis confirmed that the pO2 was causally
related to the T cells infiltration. Surprisingly, the pO2 spike was detected even though few (,46104) T cells actually ingress
into the CNS and with minimal tumor shrinkage. These results indicate the high sensitivity of this approach and its utility as
a non-invasive surrogate biomarker of anti-cancer immunotherapeutic response in preclinical models.
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Introduction
Malignant gliomas are the most common type of primary brain
tumor and a significant public health problem, with more than
14,000 new cases diagnosed each year in the US [1]. Glioblastoma
multiforme (GBM) is by far the most common and most malignant
of the glial tumors. Patients diagnosed with GBM have a median
survival of approximately 3 months if untreated. Surgical removal
is generally the first stage of treatment followed by radiation and/
or chemotherapy. Recent clinical trial results show that concom-
itant temozolomide and radiotherapy improved the 2-year survival
to 27.2% compared to only a 10.2% survival rate for patients
receiving radiation therapy alone [2]. Although this trial
demonstrates a significant advancement in the treatment of
GBM, novel strategies are required to better treat patients with
this aggressive cancer.
Immunotherapy using live cells has opened up new avenues for
targeting brain tumors with minimal damage to healthy tissues
[3,4,5,6,7]. We recently demonstrated that following intravenous
transfer of ex vivo activated tumor-specific Tc1, but not Tc2,
cytotoxic CD8+ T cells traffic to CNS tumor sites and mediate a
potent CNS anti-tumor response [8]. However, key questions
remain unanswered regarding the mechanisms of immune cell
entry and function in the CNS.
The successful development of novel immunotherapeutic agents
hinges upon finding biomarkers that are able to monitor the
therapeutic response in vivo. Often, disease biomarkers involve
accessible tissue samples such as blood; however, for cell therapies,
an imaging biomarker may be preferable to confirm cell delivery
to the target site, and potentially provide a non-invasive tool for
the therapeutic response. In the early development of preclinical
cancer therapeutic candidates, significant curative outcomes or
tumor shrinkage may not occur. Nonetheless, sensitive surrogate
biomarkers are needed to confirm therapeutic delivery to the
tumor cells and provide real-time feedback about any incremental
anti-tumoral efficacy.
Tumor oxygenation, an important aspect of tumor physiology,
has been shown to correlate with tumor angiogenesis, recurrence,
and malignant progression [9]. Measurement of tumor oxygena-
tion may provide new avenues for the development of novel
therapies such as hypoxia-activated pro-drugs and hypoxia-specific
gene therapy [10]. More importantly, tumor oxygen levels can be
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a critical factor determining the tumor response to radiation and
chemotherapy [11,12]. Thus, noninvasive measurements of tumor
intracellular partial pressure of oxygen (pO2) may have profound
implications to further our understanding of tumor biology and in
the development of advanced cancer therapies.
Prior work from our laboratory has established PFC cell
labeling and tracking methods using 19F magnetic resonance
imaging (MRI) [13]. In this approach, isolated cells of interest are
labeled ex vivo using a PFC emulsion designed for uptake by non-
phagocytic cells. Following transfer to the subject, labeled cells are
tracked in vivo using fluorine-19 (19F) MRI with high specificity for
the labeled cells. Building on these cell tracking technologies, a
logical extension is to exploit known oxygen-sensing properties of
the PFC molecules inside the cell.
PFC emulsions have previously been used to measure pO2 in
vivo using MRI techniques [14,15,16,17,18,19]. The PFC molecule
perfluoro-15-crown-5 ether (PCE), with twenty fluorine atoms
having an equivalent chemical shift, is a molecule that is well
suited for 19F magnetic resonance spectroscopy (MRS) and MRI.
PCE dissolves paramagnetic oxygen, thereby decreasing the 19F
spin-lattice relaxation rate (R1) [14,20,21]. The
19F R1 of PCE is
linearly proportional to the oxygen concentration in proximity to
emulsion droplets. Tissue oxygenation in vivo can be determined
using a standard calibration curve correlating PCE relaxation rates
to pO2 [22].
In this study, we aimed to detect and characterize putative
tumor pO2 changes that occur following glioma/T cell interac-
tions. Our approach uses intracellular labeling of glioma cells with
PFC ex vivo prior to implantation into the CNS [13]. In established
tumors, immunotherapy was performed using intravenously
infused MHC-matched, glioma antigen-reactive CD8+ T cells
from Pmel-1 mice [23]. Immunohistochemistry (IHC) and flow
cytometry analysis were used to further confirm our in vivo findings.
These data show that an increase in pO2 can reliably be observed,
even though relatively few T cells actually ingress into the CNS
tumor. Overall, these results show that these non-invasive
intracellular oximetry methods have high sensitivity and cell
specificity.
Materials and Methods
Pmel-1 mouse-derived cytotoxic T cells
All animal protocols were approved by the Carnegie Mellon
University and/or University of Pittsburgh institutional animal
care and use committee (IACUC). All mice received humane care
in compliance with the Guide for the Care and Use of Laboratory Animals
published by the National Institute of Health. T cells were
obtained from splenocytes of Pmel-1 mice (Jackson laboratories,
Bar Harbor, ME). Pmel-1 mice are transgenic for a T cell receptor
(TCR) recognizing human glioma antigen hgp10025–33 [23]. The
hgp100-specific TCR allows for targeting of tumor cells expressing
the cross-reactive murine gp10025–33 epitope on the major
histocompatibility complex H-2Db. The CD8+ T cells were
enriched from Pmel-1 splenocytes using magnetic cell sorting
(Miltenyi Biotec, Boston, MA) and stimulated with the hgp10025–
33 peptide (5 mg/ml) and 100 U/ml recombinant human inter-
leukin-2 (rhIL-2) in the presence of irradiated (3,000 rad)
splenocytes from C57BL/6 mice (Jackson Laboratories) used as
feeder cells. At 48 hours after initial stimulation, the cells were re-
stimulated under the same conditions and harvested on day 7. The
CD8+ T cells for control experiments were isolated from wild-type
C57BL/6 mouse splenocytes using magnetic cell sorting (Miltenyi
Biotec) and stimulated in vitro using 100 U/ml rhIL-2 and 5 mg/ml
CD3 antibody.
For IHC assays, control T cells were labeled with the fluorescent
dye, carboxyfluorescein succinimidyl ester (CFSE, Vybrant cell
tracer kit, Molecular Probes Inc., Eugene, OR) after stimulation.
The cells were co-incubated at 37uC with 5 ml of 10 mM CFSE in
PBS. After 15 min, the cells were washed and then incubated in
complete cell medium with RPMI 1640 supplemented with 10%
heat-inactivated fetal bovine serum, 100 units/ml penicillin,
100 mg/ml streptomycin, and 10 mmol/l L-glutamine (Life
Technologies Inc., Grand Island, NY) at 37uC for 30 min prior
to intravenous injection to the animals.
Ex vivo PCE labeling of GL261 cells
The mouse GL261 glioma cell line was kindly provided by Dr.
Prins (University of California at Los Angeles). This cell line
expresses the human glioma antigen hgp10025–33 and produces
aggressive tumors in syngeneic mice [24]. The GL261 cell line was
maintained in complete cell medium in a humidified incubator at
5% CO2 and 37uC.
GL261 glioma cells were labeled ex vivo with PCE emulsion (CS-
580, Celsense, Inc., Pittsburgh, PA). Briefly, 90% confluent GL261
cells in a 10 cm culture dish were co-incubated with 7.5 mg/ml of
PCE emulsion in serum-free media using similar materials and
methods described previously [13]. Cell viability was examined
after the labeling using the trypan blue exclusion assay and
determined to be .90%. After 4 hours of incubation at 5% CO2
and 37uC, the cells were washed three times in PBS prior to
inoculation.
To measure the PCE content of labeled cells, 19F nuclear
magnetic resonance (NMR) was used. Labeled cells (16106) were
pelleted in a 5 mm NMR tube and 200 mL of 1% trifluoroacetic
acid (TFA) was added as a standard. The sample temperature was
maintained at 37uC, and NMR spectroscopy was performed at
11.7 T using a Bruker spectrometer (Bruker Biospin, Billerica,
MA) with a recycle delay time of 8 s and 32 averages. The spectral
peaks of PCE and TFA were integrated to calculate the mean 19F
content per cell as previously described [25].
Glioma model
Female C57BL/6 mice (n = 16), 6–8 weeks old (Jackson
Laboratories) were anesthetized with a cocktail of ketamine
(Sigma Inc., St. Louis, MO) at 40–95 mg/kg and Xylazine (Lloyd
Inc., Shenandoah, IA) at 5–20 mg/kg. Using a stereotaxic
instrument, two holes were drilled in the skull 1 mm anterior
and 2.3 mm lateral to either side of the bregma using a surgical
drill. PCE labeled GL261 glioma cells (56105) suspended in PBS
were inoculated into the right striatum (day 0). Unlabeled GL261
cells (0.56106) were injected into the left striatum. At day 3, CD8+
T cells (26107) from Pmel-1 mice were injected intravenously via
tail vein (n = 7) using a PBS vehicle. In the control T cell group
(n= 4), the same number of CD8+ T cells from wild-type C57BL/
6 mice were used. A second control group did not receive any T
cell treatment (n = 5).
Calibration of pO2 response
The response of R1= 1/T1 to pO2 for PCE [26] was
determined from emulsion samples held at different oxygen
pressures, ranging from 0 to 760 mm Hg. These samples were
prepared by bubbling mixtures of O2 and N2 gasses for 15 minutes
in NMR tubes, and then the tubes were sealed. Samples were
prepared in triplicate for each pO2 value. The
19F R1 was
measured for each sample at 37uC using an 11.7 T Bruker NMR
spectrometer and a saturation-recovery sequence pulse sequence
[25]; each recovery curve was fit to a mono-exponential equation.
The R1 values for triplicate pO2 samples were averaged. Data
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were fit using a linear least square method to yield a linear
relationship between R1 and pO2 given by (Fig. 1, R
2.0.99)
R1~0:0022 pO2½ z0:697 ð1Þ
In vivo 19F MRI
Animals underwent 19F/1H MRI longitudinally after tumor
implantation at days 3, 5, 7, and 12. MRI experiments were
performed using a Bruker 11.7 T vertical-bore micro-imaging
system. The animals were anesthetized with 0.9% isoflurane in
67% O2 and 33% N2O and maintained at 37uC during the
experiments. A reference capillary with a 10% diluted PCE
emulsion in 2% agarose was placed close to animal’s head in the
image field of view (FOV). The 1H MRI images were acquired to
provide anatomical information of the brain using a spin-echo
sequence using the following parameters: repetition time (TR)/
echo time (TE) = 700/12 ms, number of averages = 2, slice
thickness = 2 mm, number of slices = 8 slices, FOV=464 cm2,
and matrix size = 2566256. Co-registered 19F images with the
same FOV and slice thickness were acquired using the rapid
acquisition with relaxation (RARE) sequence; the parameters
were: TR/TE=1200/12 ms, RARE factor = 8, number of
averages = 128, and matrix size = 64664 and scan time
,20 min. The longitudinal loss of the total 19F signal in the
tumor volume calculated from the total integrated tumor signal,
normalized to both the signal of the calibrated external reference
and the initial tumor 19F signal measured at day 3; the image
analysis was performed using the Voxel Tracker software program
(Celsense). The 19F R1 values were measured using a saturation-
recovery point resolved spectroscopy (PRESS) sequence, with a
single voxel encompassing the entire tumor mass (voxel
size = 86868 mm3). Twelve TR values were used to measure
the R1 relaxation rate, ranging between 0.15 and 10 s (total
acquisition time ,50 min). The R1 was calculated by integrating
the 19F spectral peak acquired at different TR values, and the
resulting values were fit using a three-parameter single exponential
equation [19]. The mean pO2 of the tumor cells was then
calculated using Eq. [1].
IHC analysis
Two days after T cell infusion, additional animals (n = 3) were
sacrificed for IHC staining. Anesthetized animals were perfused
transcardially first with PBS to remove blood, followed by 4%
paraformaldehyde (PFA) in PBS. The intact brain tissue was
dissected from the skull and stored in 4% PFA overnight. The
fixed brain was paraffin embedded and sliced into 8 mm sections
encompassing the tumor injection site. Brain tissues were stained
by Vectashield hard-set mounting medium with 49,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories Inc., Burlingame, CA).
Fluorescence activated cell sorter (FACS) analysis
To quantitate tumor infiltrating lymphocytes (TILs), additional
animals received Pmel-1 (n = 3) or wild-type (n = 2) T cells three
days after tumor inoculation. Two days after T cell infusion,
animals were perfused with PBS through the left cardiac ventricle
and sacrificed. Brain tissues were mechanically minced, re-
suspended in 70% Percoll solution (Sigma-Aldrich, St. Louis,
MO), overlaid with 37 and 30% Percoll, and centrifuged for
20 min at 5006g. Enriched TIL populations were recovered at the
70–37% Percoll interface. TILs from animals in the same group
were pooled together. The wild-type T cells were stained with
fluorescent dye-conjugated antibodies, including: anti-CD3
(17A2), anti-CD8 (53-6.7), and anti-CD4 (GK1.5) (eBioScience
Inc., San Diego, CA). For Pmel-1 T cell quantification, we used
the H-2D (b)/KVPRNQDWL/hgp10025–33 tetramer (National
Institute of Health tetramer core facility at Emory University).
FACS data were obtained using a BD Accuri C6 flow cytometer
(Ann Arbor, MI) and analyzed using Venturione software (Applied
Cytometry, Sheffield, UK).
Statistical analysis
All measurements are presented as mean 6 standard deviation
(SD). The R1 and pO2 in three different animal groups, i.e.,
antigen-specific Pmel-1 T cells, wild-type T cells, and control, were
compared by one-way analysis of variance (ANOVA). If there
were statistical differences, multiple pairwise comparisons were
performed using Tukey’s test with a confidence interval of 95%. P
values less than 0.05 were considered statistically significant.
Results
NMR of GL261 cell pellets
The average fluorine content per GL261 cell was determined to
be ,2.561012 fluorine atoms/cell using 19F NMR analysis [25].
The minimum cell detection sensitivity for 19F cell tracking at a
comparable level of cell loading is on the order of 103–104 cells per
voxel [13]. The intracellular localization of PCE droplets was
confirmed using confocal microscopy in 9L tumor cells [25].
Because there are a large number of PCE droplets, on the order of
104, following potential mitosis in vivo, daughter cells should
contain approximately equal amounts of PCE. Internalization of
PCE emulsion droplets had minimal effect on the cell viability in
vitro via trypan blue exclusion (data not shown).
In vivo MRI of pO2
Figure 2 shows 19F/1H MRI images of glioma cells at day 5
after tumor implantation. A solid tumor is visible in the right
striatum in the T2-weighted
1H image, which co-localizes with the
Figure 1. In vitro calibration curve for R1 =1/T1 versus pO2. Here,
solid circles represent average 19F R1 measurements of six oxygen
partial pressure values, each in triplicate, ranging from 0% to 100%
oxygen in a saturated O2/N2 mixture of PFC emulsion in water. The solid
line is the calibration curve fit by the linear least squares method
(R2 = 0.99). Data were collected at 11.7 T and 37uC. 100% oxygen is
equivalent to 760 mm Hg. (The R1 error bars are smaller than the point
size.)
doi:10.1371/journal.pone.0059479.g001
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19F ‘hot-spot’ image. No 19F signal was detected on the
contralateral side of the striatum inoculated with unlabeled cells.
The peak 19F image signal-to-noise ratio in the tumor was ,35.
Figure 3A (left axis) displays the longitudinal dynamics of tumor
pO2 in the glioma in vivo, with and without the infusion of
immunotherapeutic T cells. Notably, approximately two days after
Pmel-1 T cell injection, the tumor cells exhibited a significant
increase in average R1 value (0.9260.02 s
21) when compared to
wild-type T cell (0.8360.03 s21) infusion and (no cell) control
(0.8460.01 s21) groups (Fig. 3A, right axis, p,0.05). The
increased R1 reveals pronounced elevation of oxygen tension
inside the glioma cells (Fig. 3A) when Pmel-1 specific T cells were
infused compared to either wild-type T cell infusion or no-cell
control groups (94.368.4 mm Hg versus 49613 mm Hg and
54.464.4 mm Hg, respectively, p,0.05). We observed that the
pO2 increase is short-lived, and after this transient spike, tumor
pO2 in the Pmel-1 T cell group gradually decreased and remained
comparable to the other groups beyond seven days after tumor
implantation (p =NS). The observed net 19F signal decreased
longitudinally (Fig. 3B), presumably due to dilution due to cell
division and cell death. We note that the PCE agent is not
degraded by the cell nor exocytosed [13].
Ex vivo analysis
IHC in excised brain tissue confirmed (Fig. 4A) that Pmel-1
CD8+ T cells infiltrated the GL261 tumor two days after cell
infusion, when the oxygen spike was observed in vivo. Figure 4A
shows a detectable, but sparse, distribution of Pmel-1-specific T
cells inside the tumor mass. A single cell suspension was prepared
from whole-brain and analyzed using quantitative FACS analysis
methods [27]. In the brain cell suspension, Pmel-1-specific T cells
could be detected by FACS (Fig. 4B–C), where the average
number (n = 3) of cells was approximately 44,000 per brain (n = 3),
and each brain contained two Gl261 tumors. In the control group,
where wild-type CD8+ T cells were infused, significant T cell
trafficking into the brain was not observed via FACS (Fig. 4D).
Discussion
This study demonstrates, for the first time, the dynamics of the
tumor intracellular pO2 in vivo following treatment with TILs.
Overall, these data show that the increase in tumor pO2 can
reliably be observed using MR techniques, even though relatively
few T cells actually ingress into the CNS tumor. We hypothesize
that the magnitude and duration of the pO2 spike could provide
an early surrogate marker of anti-tumor activity.
Immunotherapeutic approaches have emerged as a new avenue
for malignant glioma treatment. Taking advantage of the body’s
own defense system, immunotherapeutic strategies specifically
target tumor cells without damaging the surrounding healthy
tissue [7,28]. Existing immune therapy regimes can be categorized
into three major types, i.e., general immunomodulation [29,30],
cancer vaccines [5,31,32], and adoptive cell transfer (ACT) [3,33].
In ACT therapies, the TILs are harvested from the body,
expanded and stimulated ex vivo, then transferred back to the host
to elicit an immune response against malignancies. This technique
has been used and shown to be effective in eradicating melanomas,
and recent efforts have focused on applying ACT to other cancer
forms including malignant glioma [7]. In our study, two days after
ACT therapy, a transient ‘spike’ in tumor oxygenation was
observed. This improvement in tumor intracellular pO2 was
associated with the infiltration of cytotoxic T cells from circulation
(Figs. 4A–C). However, the elevated pO2 decayed after two days,
which may indicate that the small number of Pmel-1-specific
CD8+ T cells that ingress into the tumor were not sufficient to
provide a sustained increase in pO2, nor obvious tumor shrinkage.
In contrast, other studies using similar MRI methods [25] in a 9L
glioma model in the rat brain showed a sustained pO2 elevation
Figure 2. In vivo 19F/1H MRI of mouse glioma showing 19F
labeled tumor cells. Panel (A) is a 1H axial image and panel (B) is a
composite 19F and 1H image of PCE labeled GL261 glioma cells in the
right striatum at day 5 post tumor inoculation. The 19F image is
rendered in a hot-iron intensity scale, and the 1H is in gray scale.
Unlabeled GL261 cells were injected into the contralateral striatum in
the same imaging plane. Diluted PCE emulsion (9.8 mg/ml) in 2%
agarose was used as a 19F reference (shown at bottom).
doi:10.1371/journal.pone.0059479.g002
Figure 3. In vivo longitudinal pO2 changes of CNS GL261 tumor.
Panel (A) shows the pO2 (left axis) and R1 (right axis) values. Panel (B)
displays the total normalized 19F signal of the tumor over time. On day
3, Pmel-1 antigen-specific CD8+ T cells or wild-type T cells were injected
into the corresponding groups, and the control group received no cells.
Here, (*) denotes p,0.05 comparing Pmel-1 group with wild-type T cell
and no-cell groups.
doi:10.1371/journal.pone.0059479.g003
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after a single infusion of the potent chemotherapeutic agent bis-
chloroethylnitrosourea (BCNU).
Future efforts need to be directed at improving ACT to exert a
persistent tumor killing effect, for example, as detected by the pO2
response. When combined with systemic IL-2 administration, it
has been show that ACT effectively suppressed tumor growth in
glioma-bearing rats [3]. It was also reported that cytokine and toll-
like receptor-3 agonist (Poly-ICLC) facilitate ACT trafficking to
the tumor site, thus helping to kill tumor cells and prolong the
survival of glioma-bearing animals [34]. We note that this same
study [34] reported the same order of magnitude of CD8+ T cells
(,104) entering the CNS tumor as the present study. Selection of a
subset of CD8+ T cells with memory potential and optimization of
in vitro stimulation conditions for ACT also have been shown to
help mediating tumor clearance [35]. Further, depletion of
immune response suppressor cells, i.e., regulatory T cells,
facilitates the tumor-killing process [36]. The evaluation of these
next-generation preclinical experiments using the sensitive surro-
gate pO2 markers described herein is the subject of future work.
Tumor oxygenation is a key factor determining tumor growth,
metastasis, and the response to treatment. We detected a moderate
decreasing trend in the mean tumor pO2 in the control group with
tumor growth (Fig. 3A), which echoes the findings in previous
studies [17]. In response to the TIL therapy, an increase in
oxygenation was observed (Fig. 3A). The increase was commen-
surate with the appearance of Pmel-1 T cell trafficking to the
tumor site, as confirmed by IHC and FACS analysis (Figs. 4A–C).
The exact mechanism(s) for the elevation in pO2 is unknown.
These infiltrated cytotoxic T cells have a TCR that recognizes
gp100, thereby inducing tumor apoptosis [37]. We speculate that
tumor cells undergoing apoptosis likely have altered intracellular
pO2 levels. Alternatively, another possibility is that when tumor
cells were killed, the PCE emulsion was released to the
extracellular space and exposed to a higher pO2 or taken up by
resident phagocytic cells. However, detailed histological studies in
a rat glioma model using labeled 9L cells show that the PCE from
apoptotic cells tends to clear and disperse from tissue over time.
There is the possibility that a small amount of observed PCE is
extracellular from dead cells before the material it is cleared, and
this is a limitation of the technique. Theoretically, other factors
may influence the 19F R1 and/or intracellular pO2, including
arterial pO2, cerebral blood flow and perfusion [38], metabolic
processes [39], anesthetics [40], and body temperature. In our
study, all animals were mechanically ventilated and maintained
under constant anesthetic conditions and temperature regulated at
37uC during imaging. Similar experiment settings yielded a stable
arterial pO2 level in rat [25], thus we believe that we have
minimized the confounding effects of arterial pO2, anesthetics, and
body temperature.
In our study, the pO2 was measured by assuming uniform
oxygenation in a relatively small solid tumor. The baseline tumor
pO2 measured in our study was in the similar range as previous
studies [41], but lower than that in normal cerebral tissue [15]
indicating the presence of hypoxia in an early-stage tumor mass.
Hyperoxic gas (67% O2 and 33% N2O) was used during MRI
study. Therefore, the absolute pO2 values are not physiologic
values. Tumor oxygenation is likely heterogeneous within a tumor
mass, but our current measurements were not designed to capture
spatial heterogeneity [17,38]. Future studies that examines the
spatial distribution of pO2 using T1 mapping methods may further
our understanding of pO2 changes and its role in tumor
physiology.
Ex vivo labeling of GL261 was used instead of in situ labeling in
this study. In previous studies, the PCE emulsion was introduced
i.v., or injected directly intratumoral [14,16,18,19]. For i.v.
delivery, generally a large PCE dose is injected systemically and,
at best, only a small fraction of the PCE is delivered to the tumor
tissues, which may be visible several days post-administration. The
PCE emulsion droplets are sequestered predominantly in the
periphery of the tumors because of the leakage in the tumor
vasculature [17,18], or phagocytosis by tumor-associated macro-
phage [14,16]. The above routes of administration generally result
in very non-uniform distribution of PCE emulsion deposits in the
tumors, and the pO2 sensing may be from an ill-defined cell type
or extracellular. Ex vivo labeling has the advantage of uniform
labeling of tumor cells, and daughter cells contain similar amount
of PCE after cell division. Ex vivo labeling also ensures specificity to
tumor cells. It is not possible to use the techniques described herein
with spontaneous tumor models or with unlabeled implanted
tumor models. Also, the technique is best suited for tumors that are
relatively young, i.e., prior to a large number of cell divisions to
ensure a relatively uniform PFC distribution. Moreover, inhomo-
geneity in cell division is possible, which may result in some
regions falling under the 19F detection threshold and thus not
being represented in the overall pO2 level.
In this study, an oxygen sensitive PFC compound, PCE, was
used for the measurement of pO2. PCE has a single
19F NMR
peak and is a sensitive molecule for MRI and displays high
sensitivity to pO2 changes (Fig. 1). Other PFC compounds for
oximetry including hexafluorobenzene (HFB) [42] and perfluor-
ooctylbromide (PFOB) [43] have been discussed in the literature
[19,21]. We note that the particular PCE emulsion formulation
that was used (CS-580, Celsense, Inc.) is designed to be taken up
by any cell type in culture regardless of its phagocytic properties
Figure 4. Ex vivo analysis shows the infiltration of CD8+ T cells
to brain and glioma. Panel A shows IHC of fluorescently labeled
Pmel-1 CD8+ T cells. Animals were infused with T cells (26107) and
sacrificed for IHC staining two days after cell infusion. Sparse T cells are
shown at the arrows. Panels B–C show quantitative flow cytometry of
Pmel-1, hgp100-specific T cells in brain cell suspension with CD8+ (B)
and CD3+ (C) gating. Panel D shows quantitative flow cytometry of
wild-type T cells. Here, PE = Phycoerythrin, FITC = Fluorescein isothiocy-
anate, and TIL = tumor infiltrating lymphocytes.
doi:10.1371/journal.pone.0059479.g004
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and without the use of transfection agents, thus any (cancer) cell
type can be labeled.
The most widely used technique to measure tumor pO2 is the
polarographic oxygen electrode method [9,44]. Electrode mea-
surements are invasive and several penetrations are required to
sample the tumor volume; furthermore this technique is not
suitable for longitudinal study of deep-seated tumors. Non-invasive
imaging methods for detecting tumor hypoxia are reviewed
elsewhere [45] and include positron emission tomography,
electron paramagnetic resonance (EPR) imaging, and using
near-infrared spectroscopy. Of these imaging methods, only
EPR using implantable micron-sized crystalline probes can
provide a quantitative measurement of pO2.
Overall, in this study, a preclinical 19F MRI method was
developed to monitor rodent tumor oxygen dynamics in vivo
associated with adoptive immunotherapy. The potential applica-
tions of our methods are not limited to tumor models. It may also
be valuable to monitor cellular metabolism in different cell types
where intracellular oxygenation plays a critical role, for example,
to evaluate anti-inflammatory therapeutics involving macrophag-
es.
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